On June 26 and July 3, 2015, the fifth and sixth subjects were treated in our ongoing Canadian study of MDMA-assisted psychotherapy for PTSD. The sixth subject was enrolled on June 29. Led by Principal Investigator Ingrid Pacey, M.D., in Vancouver, B.C., this Phase 2 study is treating up to 12 subjects with chronic, treatment-resistant PTSD from sexual assault, violent crime, military service, or any other cause. Mark Haden, Chair of the Board of Directors of MAPS Canada, reflects on the media attention the study has been receiving: “We had 15 minutes on CBC national radio, a feature article in Maclean’s (Canada’s most prominent weekly magazine), and CBC’s high-profile show “Ideas” is producing two new shows dedicated to psychedelics,” Haden writes. “MAPS Canada is not just developing a better treatment for PTSD, but also having an impact on public perception of the vast potential of psychedelic medicine.”
